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Abstract 
Objective: Protein microarrays provide a high-throughput platform to measure protein interactions and associated 
functions, and can aid in the discovery of cancer biomarkers. The resulting protein microarray data can however be 
subject to systematic bias and noise, thus requiring a robust data processing, normalization and analysis pipeline to 
ensure high quality and robust results. To date, a comprehensive data processing pipeline is yet to be developed. Fur-
thermore, a lack of analysis consistency is evident amongst different research groups, thereby impeding collaborative 
data consolidation and comparison. Thus, we sought to develop an accessible data processing tool using methods 
that are generalizable to the protein microarray field and which can be adapted to individual array layouts with mini-
mal software engineering expertise.
Results: We developed an improved version of a previously developed pipeline of protein microarray data process-
ing and implemented it as an open source software tool, with particular focus on widening its use and applicability. 
The Protein Microarray Analyser software presented here includes the following tools: (1) neighbourhood background 
correction, (2) net intensity correction, (3) user-defined noise threshold, (4) user-defined CV threshold amongst 
replicates and (5) assay controls, (6) composite ‘pin-to-pin’ normalization amongst sub-arrays, and (7) ‘array-to-array’ 
normalization amongst whole arrays.
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Introduction
Protein microarrays are a high-throughput technology 
that can measure protein interactions and associated 
functions, with potential uses in cancer biomarker dis-
covery [1–14]. We have previously developed a custom 
cancer-specific protein array which measures antigen-
specific antibodies present in patient blood [15, 16]. 
These are quantified using fluorescently-labelled anti-
human IgG antibodies and a microarray scanner [17]. 
However, the resulting data can be subject to system-
atic bias and noise, and robust data processing and nor-
malization is required to ensure high quality data. DNA 
microarray tools are generally unsuitable for this purpose 
given the different assay setup, objectives and statisti-
cal assumptions used. Although several protein micro-
array-specific tools are available [18–25], none of these 
include a composite suite of methods that we deemed as 
essential. Furthermore, no consistency is seen amongst 
research groups, which impedes collaborative data con-
solidation and comparison. Thus, we sought to develop 
a generic protein microarray data processing tool that is 
readily adaptable to any array layout and should thereby 
provide valuable new insight in the field by enabling col-
laborative data analysis of new and existing datasets.
Main text
‘CT100 Analyser’
Our group has previously developed ‘CT100 Analyser’ 
[17], which included the following methods:
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Neighbourhood background correction
Net intensities are usually calculated by subtracting 
local background intensities from raw intensities. How-
ever, printing, assay and handling artefacts may lead 
to artificially increased local background intensities, 
which thereby skew the calculated net intensities. Local 
background intensities are replaced with median sur-
rounding neighbourhood corrected intensities accord-
ing to Zhu et al. [24].
Corrected net intensity
Net intensities are recalculated by subtracting the cor-
rected background intensity from the raw intensity for 
each spot.
Noise threshold
Non-specific binding can result in background noise 
that affects antigen-specific net intensity calculations. 
In addition to experimental methods for reducing noise 
during array fabrication and assay, a noise threshold 
can be applied to remove all intensities that are not sig-
nificantly above background. All spots containing a cor-
rected net intensity of less than two standard deviations 
of the background are deemed “NOISY” and excluded.
Spot filtering
Antigens, positive controls and negative controls are 
expected to be present at least in triplicate on the array, 
as a means of assuring that the obtained data is reliable 
and equally detected across spatially distinct locations. 
At times, data is not consistent across spot replicas, 
and the resulting mean net intensity may not be indica-
tive of the true signal. Therefore, after calculating the 
mean for each set of spot replicas, the coefficient of 
variation (CV) across these replicas is also calculated. If 
the obtained CV is above 20% (user-defined), the mean 
net intensity is deemed “HIGH CV” and excluded.
Saturation occurs when the fluorescent intensity 
detected surpasses the scanner’s reading capacity, and 
as a result, this maximum value is reported alongside 
information regarding the percentage of pixels within 
the spot of interest that are saturated. To assure that 
all intensities reported are reliable, all spots that show 
saturation above 10% are deemed “SATU RAT ED”, and 
the array flagged for rescanning at a lower PMT gain 
setting.
Array filtering for a selected positive control
Positive controls are essential in all protein microar-
rays and can be used for the implementation of data 
filtering and normalization methods. Replicas of these 
controls should be well distributed across the entire 
array surface. At times, slide coating, sample loading 
or printing issues can arise and affect spot homogene-
ity and size. To investigate whether array printing was 
up to the expected standard, CVs of a selected positive 
control are calculated for each array across all replicas. 
If an array’s CV is above 20%, this array is excluded and 
flagged as a required repeat.
‘Pin‑to‑pin’ and ‘array‑to‑array’ normalization
To enhance assay throughput, multiple replica arrays can 
be printed across a single slide. However, the usage of 
multiple pins/nozzles and the replica printing action can 
lead to slight variations. Moreover, differences in micro-
array scanner PMT gain settings can complicate data 
comparison between arrays or datasets. Therefore, data 
normalization is essential to account for these variations. 
The above mentioned positive control spatially dispersed 
replicas are used for this purpose. The functionality of 
this method requires these controls to be in the defined 
static location and at three different concentrations. We 
have implemented a composite normalization method 
combining quantile normalization and total intensity 
normalization modules [26–28]. With this method, 
individual blocks within each array are normalized with 
respect to each other to minimize any effects of ‘pin-to-
pin’ variation, and whole arrays are then normalized with 
respect to each other to minimize any effects of ‘array-
to-array’ variation. This normalization method only uses 
data points and arrays that have not been flagged or dis-
carded by prior methods.
Data consolidation
After processing all raw data files with ‘CT100 Analyser’ 
an output folder is generated. The final resulting data files 
are consolidated into a single file, where each column 
represents a single array, and each row a single antigen/
control. Each data point corresponds to the mean net 
intensity of all valid replicas for each sample. Addition-
ally, flagged and discarded folders are generated contain-
ing all problematic data.
PMA—Protein Microarray Analyser
Extensive use of ‘CT100 Analyser’ highlighted opportu-
nities for further improvement and generalisation, which 
we have now addressed. The following methods were 
included:
Slide scanning using the automatic gain control (AGC) mode
Fluorescent microarray scanners have an AGC mode in 
addition to user-defined PMT gain settings. The former 
ensures that no saturating signals are detected through-
out the array thereby excluding the need to flag saturated 
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spots and rescan slides. PMA thus now allows for scan-
ning arrays using the AGC mode. However, it is impor-
tant to note that when using this setting, subsequent data 
normalization is critical.
A user‑defined antigen layout and list (.gal file)
After scanning, users create or input a.gal file accord-
ing to the specific array layout and antigen list to enable 
adequate data extraction. The functionality of ‘CT100 
Analyser’ was restricted to a fixed.gal file and any modi-
fications to the array layout required adaptation of this 
tool accordingly. Since different arrays have different con-
tent and layouts, we therefore sought to make the soft-
ware dynamic and applicable to any antigen layout, while 
maintaining the same use of positive and negative con-
trols. PMA now enables processing of raw data extracted 
with a user-defined.gal file, as long as this file is included 
in the program folder. Currently implemented meth-
ods in PMA require the inclusion of specific, statically-
defined positive and negative controls to ensure their 
correct functionality in subsequent quality control, slide 
orientation and signal normalization steps. It is therefore 
important to note this when adapting this source code to 
an alternative array layout.
Additional positive controls (e.g. anti-human IgG and 
human IgG spots, to confirm respectively the addition of 
patient serum/plasma and detection antibody) and nega-
tive controls (e.g. buffer-only and tag-only, to determine 
any non-specific immunochemical interactions) are also 
allowed for in PMA.
A user‑defined adjustable noise threshold
Despite best efforts, the amount of noise detected on 
protein arrays can be variable across different assay runs. 
As such, the noise threshold is now user-defined as n 
standard deviations of the background.
Array filtering for each positive control
The ‘CT100 Analyser’ previously used positive controls at 
three distinct concentrations for array filtering and nor-
malization purposes, conducting CV calculations and 
discarding flagged arrays using the user-defined concen-
tration of positive controls. However, it was previously 
necessary to test this function across all three concen-
trations of positive controls, requiring the user to con-
duct three separate analyses, each generating a different 
final consolidated data file. The improved PMA software 
applies this method using all three different concentra-
tions of positive controls, but proceeds with the process-
ing pipeline using the user-selected control. This ensures 
that the user is informed of which control is best for this 
purpose, and also highlights any potential printing con-
cerns that may not have been apparent previously.
An improved mean net intensity calculation
After all methods have been applied, replica spots for 
each antigen or control are averaged, and a mean net 
intensity is reported. However, a mean isn’t reported in 
two instances—when one of the replicas is “NOISY” 
(intensity below the user-defined noise threshold) or 
when the mean is “HIGH CV” (CV of the replicas above 
the user-defined percentage). This mean calculation has 
now been improved to avoid losing valid data when only 
one of the three replicas is problematic. Specifically, the 
mean is calculated when two or three of the replicas are 
available and distributed with low-variance (outlier repli-
cas excluded). As a result, skewed means are avoided and 
fewer data points are unnecessarily discarded from the 
analysis.
A user‑friendly output folder
The ‘CT100 Analyser’ output contained an excessive 
amount of information that was not user-friendly. We 
have improved the content of this output folder by only 
including the processed files that are relevant for down-
stream data analysis. These include the final consolidated 
replica and averaged data for all arrays after applica-
tion of all methods and the list of discarded arrays that 
require repetition. Additionally, this folder is dated and 
timed and includes a record of the used settings. Verbose 
processing output may also be viewed when executing 
the PMA program via the command line when additional 
information is required.
Implementation
PMA is a desktop-based offline Java tool that supports.
txt file formats, which are the standard protein microar-
ray image acquisition and analysis software output.
Running the software
PMA includes: (1) neighbourhood background correc-
tion, (2) net intensity correction, (3) user-defined noise 
threshold, (4) user-defined replicate and (5) control CV 
threshold, (6) composite ‘pin-to-pin’ and (7) ‘array-to-
array’ normalization (Fig. 1).
The software can be executed via the GUI (.jar file, 
Fig.  2) or command line (java -jar ProteinMicroarray-
Analyser.jar  >  output.txt). Individual.txt raw data files 
for each array assayed should be placed in a single folder, 
and this folder should be selected by the user as a new 
dataset (select file—new dataset—select folder contain-
ing raw data.txt files). The user is then required to either 
input personalized settings or to select the default setting 
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option. The default settings are based on previously pub-
lished array layouts and as such should be reviewed and 
adjusted accordingly. After submitting the user-defined 
settings, the next interface lists the methods to be run 
on the dataset, after which the analysis is initiated and a 
results folder is generated.
After the software run
The results folder is automatically named with the date 
and time of the run, and includes two consolidated files. 
These tab-delimited files include the final RFU values 
across arrays with all replicas (ProteinMicroarrayAna-
lyser.AllAntigenReplicateValues.txt) or single averages 
(ProteinMicroarrayAnalyser.consolidated.txt).
Four separate tab-delimited CV evaluation files may 
also be included in this results folder. These are gener-
ated using low (listOfArraysToDiscard.low.txt), medium 
(listOfArraysToDiscard.med.txt), high (listOfArraysTo-
Discard.high.txt) or the selected (listOfArraysToDiscard.
overall.txt) positive controls. These include lists of arrays 
that have failed the user-defined CV threshold with that 
particular control, and thus require repetition.
The debug output enables users to obtain specific 
details of each array processed, if required. Manual vis-
ualization of all scanned arrays is recommended and 
should assess spot-to-spot variation, spot homogeneity, 
background variation, signal-to-noise ratio and saturated 
pixels [17].
Data analysis
The file used for analysis is the average consolidated 
file, and can be viewed using a spreadsheet or text edi-
tor. Rows correspond to antigens, columns to arrays, 
and array names to raw file location. Data points con-
sist of RFU values, or the terms “NOISY” or “HIGH CV”. 
“NOISY” data should be set to zero and “HIGH CV” anti-
gens excluded from analysis. A worked example demon-
strates the implementation of this tool in more detail (see 
Additional files 1, 2).
There are a large number of readily available down-
stream data analysis tools that can be used on protein 
microarray data, and as such we did not include these. 
Tool selection should depend on the analysed cohort and 
research question.
Limitations
PMA functionality requires specific positive and nega-
tive controls in a defined static location, does not permit 
individual method usage or include subsequent statistical 
data analysis methods.
Fig. 1 Schematic of the Protein Microarray Analyser data processing 
and normalization pipeline. Extracted raw data is corrected and 
filtered to remove or flag problematic data and obtain high quality 
results that can then be used across a multitude of appropriate data 
analysis tools
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